NEWS

NEWS

Total 102

22
NeoImmuneTech Receives U.S. FDA Clearance of IND Application for Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
2020-07-20
21
NeoImmuneTech Announces Clearance for Investigational New Drug Application of NT-I7 (efineptakin alfa) in Adults with Mild COVID-19
2020-07-15
20
NeoImmuneTech Announces First Patient Dosed in Phase 1b/2a Study of NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Patients with Relapsed/Refractory Advanced Solid Tumors
2020-06-25
19
NeoImmuneTech Receives FDA Orphan Drug Designation for NT-I7 (efineptakin alfa) for the Treatment of Progressive Multifocal Leukoencephalopathy
2020-06-15
18
NeoImmuneTech Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate NT-I7 (Hyleukin-7™) in Combination with Nivolumab
2020-04-09
17
NeoImmuneTech Enters into Exclusive License Agreement with Ubix Therapeutics to Develop Drug Candidates Including T Cell Suppressor Blockade
2020-03-23
16
NeoImmuneTech Appoints Gene Namgoong as Chief Operating Officer
2020-01-30
15
NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase 1b/2a Study of Hyleukin-7™ (NT-I7) and KEYTRUDA® (Pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors
2020-01-28
14
NeoImmuneTech Announces Clinical Collaboration to Evaluate Hyleukin-7™ (NT-I7) in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
2019-12-11
13
NeoImmuneTech Announces Formation of Scientific Advisory Board to Support Development of its Immunotherapeutics Portfolio
2019-11-13

<<<6 7 8 9 10 >>>